Teva says real — world data show UZEDY cuts schizophrenia patients’ monthly healthcare costs by USD 1,036.70 vs PP1m
Teva disclosed new real-world studies on UZEDY at Psych Congress, with results already presented during the Sept. 15-19, 2026 meeting. Data in schizophrenia showed UZEDY kept more patients on therapy than competing long-acting injectables, supporting stronger treatment continuity. Patients on UZEDY recorded fewer emergency-care events, lowering healthcare utilization versus key long-acting injectable comparators. Teva also cited lower direct healthcare spending for UZEDY patients, translating into more than USD 1,000 per patient per month savings. In bipolar I maintenance, patients switching from oral antipsychotics to UZEDY had fewer treatment failures than those switching to another oral option. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via (Ref. ID: 202609181631OMX_____CNEWS_EN_GNW1001263357_en) on September 18, 2026,
Teva disclosed new real-world studies on UZEDY at Psych Congress, with results already presented during the Sept. 15-19, 2026 meeting. Data in schizophrenia showed UZEDY kept more patients on therapy than competing long-acting injectables, supporting stronger treatment continuity. Patients on UZEDY recorded fewer emergency-care events, lowering healthcare utilization versus key long-acting injectable comparators.
Teva also cited lower direct healthcare spending for UZEDY patients, translating into more than USD 1,000 per patient per month savings. In bipolar I maintenance, patients switching from oral antipsychotics to UZEDY had fewer treatment failures than those switching to another oral option. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.
Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via (Ref. ID: 202609181631OMX_____CNEWS_EN_GNW1001263357_en) on September 18, 2026, and is solely responsible for the information contained therein. (C)